Dermata Therapeutics Inc. Common Stock

Dermata Therapeutics Inc. a clinical-stage medical dermatology company focuses on identifying developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310 which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. Dermata Therapeutics Inc. was incorporated in 2014 and is headquartered in San Diego California.